As the main active component of ICA metabolite, ICII can suppress Aβ production via promoting the non-amyloidogenic APP cleavage process and markedly decrease the phosphodiesterase-5A (PDE5A) expression to treat Alzheimer’s disease (Yin et al., 2016). Here, APP is linked to early-onset autosomal dominant Alzheimer disease.